August 19, 2025—Vilnius, Lithuania—Oxipit, a leading AI-driven healthcare technology company, is pleased to announce that Kevin Shah has joined the company as Strategic Advisor, bringing invaluable guidance as the company builds on recent sales momentum and prepares for the launch of its upcoming MSK and CT solutions.
With 18 years of experience in healthcare IT, Kevin Shah is widely recognized as a thought leader in advancing AI adoption in radiology. His deep market knowledge and proven commercial experience align closely with Oxipit’s mission to lead the future of autonomous radiology—delivering trusted AI solutions that empower equitable, precise healthcare, transform diagnosis, and improve patient care worldwide.
Kevin joins Oxipit’s strong advisory team alongside Prof. Erik Ranschaert and Robert Epstein, MD. Together, their commercial, clinical, and industry expertise will help drive Oxipit’s mission forward at a time when radiology faces mounting backlogs, increasing imaging volumes, and growing pressure on clinicians. As recognition grows for AI’s potential to take on specific tasks independently—freeing radiologists to focus on complex cases—Oxipit’s solutions are at the forefront of shaping the radiology workflows of tomorrow.
“This is an exciting moment for Oxipit,” says Peter Corscadden, Oxipit CEO. “We’re seeing autonomous chest X-ray reporting gain traction, fulfilling orders with platform partners worldwide, and preparing for the launch of our MSK and CT solutions. It’s the perfect time to welcome someone of Kevin’s calibre to help us accelerate our growth. I’ve long admired Kevin for his deep understanding of both technology and market dynamics—and most importantly, for sharing our passion to deliver solutions that truly support clinicians and deliver measurable patient benefit.”
Kevin shares the enthusiasm: “I’ve known the team at Oxipit for many years and I’m very excited to take on this advisory role to support the team and business growth. Its great timing as the market is now maturing with these technologies entering day to day clinical use”.
He also adds, “I’m eager to work with the team as they expand into MSK and CT, which will follow the same model: Autonomous Healthy Exams Reporting, CAD Assistance, and a Quality Safety Net. I look forward to helping the team unlock the full potential of what they’ve built. I’ve been impressed with the quality of people and the real focus they show on supporting imaging professionals, whose workloads are increasing in both volume and complexity.”
About Oxipit
Founded in 2017 by experts in medicine and data science, Oxipit is a leader in AI-driven medical imaging. In 2019, the company received CE certification for ChestEye, enabling preliminary reports for 75 chest X-ray findings. Building on this success, Oxipit launched ChestLink in April 2022—the world’s first CE Class IIb-certified autonomous AI imaging application—capable of identifying normal chest X-ray studies with 99.9% sensitivity. Oxipit empowers radiologists by automating routine cases, allowing them to focus on complex and high-priority cases, while enhancing diagnostic accuracy and improving patient outcomes. Trusted by healthcare providers worldwide, Oxipit continues to advance AI-powered diagnostics, shaping the future of medical imaging.